Inside the research
Progyny, Inc.
PGNY Research profile · latest available data
Price overview
$25.44
▼ -0.53 (-2.0%)
| 52w hi | $32.36 |
|---|---|
| 52w lo | $16.30 |
| Vol | 1.11M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.28
| Short | +0.00 |
|---|---|
| Medium | +0.40 |
| Long | +0.60 |
computed 2026-09-27
Key fundamentals
Progyny, Inc.
Healthcare · Healthcare Plans
| Market cap | $1.95B |
|---|---|
| Enterprise value | $1.74B |
| Trailing P/E | 27.65x |
| Forward P/E | 10.97x |
| EV / EBITDA | 13.87x |
| P / S (ttm) | 1.49x |
| Profit margin | 6.0% |
| Return on equity | 16.2% |
| Revenue growth | +5.3% |
| Earnings growth | +78.9% |
| Debt / equity | 5.95 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.37 | |
| Sector | +0.08 | |
| Technical | +0.05 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Risk Metrics
| Beta vs SPX | 0.51 |
|---|---|
| Corr SPX | 0.16 |
| Annual vol | 50.5% |
| Annual ret | +33.9% |
| Sharpe | 0.67 |
| Max DD | -42.6% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-06 | Earnings Release, Reg FD Disclosure | read |
| 2026-05-27 | Bylaws Amendment, Shareholder Vote | read |
| 2026-05-26 | Other Material Event | read |
| 2026-05-07 | Earnings Release, Reg FD Disclosure | read |
| 2026-03-13 | Other Material Event | read |
| 2026-02-26 | Earnings Release, Reg FD Disclosure | read |
| 2026-01-12 | Earnings Release | read |
| 2025-12-17 | Officer / Director Change | read |
| 2025-11-06 | Earnings Release, Reg FD Disclosure | read |
| 2025-08-07 | Earnings Release | read |
| 2025-07-08 | Material Agreement, Earnings Release… | read |
| 2025-05-28 | Shareholder Vote | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-14 | Cummings Melissa B | Chief Operating Officer | Withheld for tax | 1.19K | $38.15K |
| 2026-07-14 | Cummings Melissa B | Chief Operating Officer | Sell | 2.24K | $70.91K |
| 2026-06-17 | Clapp Geoffrey | Chief Product Officer | Withheld for tax | 819 | $21.79K |
| 2026-06-04 | Livingston Mark S. | CHIEF FINANCIAL OFFICER | Sell | 1.92K | $48.91K |
| 2026-06-04 | Swartz Allison | EVP, GC | Withheld for tax | 339 | $8.47K |
| 2026-06-04 | Livingston Mark S. | CHIEF FINANCIAL OFFICER | Sell | 599 | $15.27K |
| 2026-06-04 | Livingston Mark S. | CHIEF FINANCIAL OFFICER | Withheld for tax | 339 | $8.47K |
| 2026-06-04 | Swartz Allison | EVP, GC | Sell | 599 | $15.02K |
| 2026-06-03 | Swartz Allison | EVP, GC | Sell | 1.20K | $30.00K |
| 2026-06-03 | Swartz Allison | EVP, GC | Withheld for tax | 676 | $16.98K |
Flow & Concentration
| Insider 180d net | -$621.34K |
|---|---|
| Insider buys / sells | 0 / 10 |
| Insider bias | Neutral |
| 13F holders | 10 |
| Top-5 share | 92.9% |
| HHI | 3,154 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| Fidelity / FMR LLC | $201.93M | 7.00M |
| State Street Corp | $87.15M | 3.02M |
| Citadel Advisors | $53.11M | 1.84M |
| AQR Capital Management | $22.99M | 797.53K |
| Millennium Management | $12.67M | 439.62K |
| Renaissance Technologies | $12.24M | 424.67K |
| Capital Research / Capital World | $8.88M | 307.97K |
| Norges Bank (Norway sovereign) | $6.15M | 213.21K |
| Bridgewater Associates | $1.49M | 51.74K |
| T. Rowe Price Group | $2.49K | 86.47K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2019–2025 · 7 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $1.17B | +81.6% | |
| Gross profit | $72.83M | +24.6% | |
| Operating income | $62.18M | +51.5% | |
| Net income | $17.11M | +46.7% | |
| Cash from ops | $188.81M | +108.9% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $25.88 | $26.05 | $25.39 | $25.44 | 1.11M |
| Sep 24 | $25.66 | $26.21 | $25.25 | $25.97 | 1.33M |
| Sep 23 | $26.10 | $26.42 | $25.64 | $25.83 | 1.35M |
| Sep 22 | $26.96 | $27.15 | $26.16 | $26.24 | 882.00K |
| Sep 21 | $27.22 | $27.25 | $26.67 | $26.86 | 821.00K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →